

Connecticut Pub. Act 23-171 Disclosure

LAGEVRIO™ (molnupiravir)

Merck Sharp & Dohme LLC (“Merck”) provides the following information to Connecticut prescribers, in accordance with Conn. Pub. Act 23-171.

The pricing information below reflects Merck’s Wholesale Acquisition Costs (“WAC”) for the Merck product(s) listed below. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the price(s) listed, depending, for example, on how the customer purchases the product(s), the availability of discounts, the wholesaler/distributor, and/or other charges.

WAC for Merck Product

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
LAGEVRIO™ (molnupiravir) 200 mg Tablets	00006-5055-09	Unit-of-use bottle of 40	\$950.00

LAGEVRIO™ has not been approved, but has been authorized for emergency use by the FDA under an Emergency Use Authorization (EUA), for the treatment of adults with mild-to-moderate COVID-19, who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

The emergency use of LAGEVRIO™ is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the FDA Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Additional Information

In accordance with Conn. Pub. Act No. 23-171, Sec. 5(2), for information on efficacy by racial and ethnic group for the product(s) listed above, if available, please refer to the **Fact Sheet for Healthcare Providers** and/or the FDA’s Drug Trials Snapshots database (available online at <https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots>).

Before prescribing LAGEVRIO, please read the accompanying [Fact Sheet for Healthcare Providers](#), including Mandatory Requirements for Administration of LAGEVRIO Under Emergency Use Authorization. The [FDA Letter of Authorization](#) and the [Fact Sheet for Patients and Caregivers](#) are also available.

The trademarks or service marks herein are owned by, licensed to, promoted by, or distributed by Merck & Co., Inc., its subsidiaries or its affiliates.

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

US-ANV-00495 10/23